Compare FTAI Aviation Ltd (FTAI) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FTAI Aviation Ltd vs Natera Inc. Common Stock — how do they compare? FTAI Aviation Ltd trades at $159.09 (market cap $17.14B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 3.3× FTAI Aviation Ltd's market cap, and FTAI Aviation Ltd pays a 1.2% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold FTAI Aviation Ltd for 24 Days and Natera Inc. Common Stock for 0 Days on average.
| FTAI | NTRA | |
|---|---|---|
Market Cap | $17.14B | $57.03B |
Volume | 3,282,791 | 1,131,157 |
Sector | Industrials | Health |
52-Week High | $310.04 | $425.64 |
52-Week Low | $152.80 | $179.42 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $20.25B | $56.18B |
Dividend Yield | 1.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FTAI Aviation trades at $166.87, up 0.81% today, but technical indicators signal a bearish trend with key support at $163 and resistance at $169. The company reported strong 2025 revenue of $2.51 billion and net income of $501 million, though recent quarters have missed EPS expectations. Recent developments include a $500 million share buyback program and a strategic acquisition of 27 Boeing 737-700 aircraft, highlighting growth initiatives in aerospace services.
The outlook is mixed: analyst consensus is unanimously bullish with a $321.25 price target, but risks include volatile cash flows and competitive pressures. Upside potential hinges on execution of the buyback and aerospace segment growth, while earnings misses and negative operating cash flow pose near-term challenges for investors.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
